Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PLYX | PRESS-RELEASE | bullish | 7/10 | Polaryx Therapeutics (PLYX) announced that the FDA has granted Fast Track Designation for PLX-200 in the treatment of La | Mar 17, 2026 |
| GRFS | PRESS-RELEASE | bullish | 7/10 | Grifols announced proof-of-concept data from its Chronos-PD program, showing biological changes in Parkinson’s disease c | Mar 17, 2026 |
| LIMN | PRESS-RELEASE | neutral | 4/10 | Liminatus Pharma announced plans to initiate a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking antibo | Mar 17, 2026 |
| CADL | PRESS-RELEASE | bullish | 8/10 | Candel Therapeutics released updated Phase 2a data for its immunotherapy aglatimagene (CAN-2409) in advanced non-small c | Mar 17, 2026 |
| KLRS | PRESS-RELEASE | bullish | 7/10 | Kalaris Therapeutics reported financial results for 2025, highlighted by positive Phase 1a data for its nAMD candidate T | Mar 17, 2026 |
| INKT | PRESS-RELEASE | neutral | 4/10 | MiNK Therapeutics announced it will report Q4 and full-year 2025 financial results on March 31, 2026, alongside a corpor | Mar 17, 2026 |
| CRVO | PRESS-RELEASE | mixed | 6/10 | CervoMed reported full-year 2025 financial results and corporate updates, highlighting positive Phase 2b data for its le | Mar 17, 2026 |
| ABEO | PRESS-RELEASE | mixed | 6/10 | Abeona Therapeutics reported its first full year of commercial operations following FDA approval of ZEVASKYN, with $5.8 | Mar 17, 2026 |
| AVXL | PRESS-RELEASE | mixed | 6/10 | Anavex Life Sciences announced preclinical data showing that its investigational drug blarcamesine improved motor functi | Mar 17, 2026 |
| CGTX | PRESS-RELEASE | bullish | 8/10 | Cognition Therapeutics presented Phase 2 SHIMMER study data showing zervimesine (CT1812) slowed decline in neuropsychiat | Mar 17, 2026 |
| XFOR | PRESS-RELEASE | mixed | 6/10 | X4 Pharmaceuticals reported Q4 and full-year 2025 financial results with $35.1M in total revenue, driven by a $28.6M lic | Mar 17, 2026 |
| GLUE | PRESS-RELEASE | bullish | 8/10 | Monte Rosa Therapeutics reported Q4 and full-year 2025 financial results alongside significant clinical progress, includ | Mar 17, 2026 |
| BCDA | PRESS-RELEASE | bullish | 7/10 | BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Cathete | Mar 17, 2026 |
| ATAI | PRESS-RELEASE | bullish | 8/10 | AtaiBeckley Inc. announced the peer-reviewed publication of positive Phase 2a data for its intranasal therapy BPL-003 in | Mar 17, 2026 |
| IBIO | PRESS-RELEASE | mixed | 6/10 | iBio, Inc. announced plans to expand its pipeline into pulmonary hypertension associated with heart failure with preserv | Mar 16, 2026 |
| LODE | PRESS-RELEASE | neutral | 3/10 | Comstock Inc. announced a webinar to discuss its year-end financial results and business updates, scheduled for March 24 | Mar 16, 2026 |
| AUTL | PRESS-RELEASE | neutral | 3/10 | Autolus Therapeutics will announce its Q4 and full-year 2025 financial results on March 27, 2026. This press release ser | Mar 16, 2026 |
| CATX | PRESS-RELEASE | mixed | 6/10 | Perspective Therapeutics (CATX) reported full-year 2025 financial results and provided a clinical update on its radiopha | Mar 16, 2026 |
| CTMX | PRESS-RELEASE | bearish | 7/10 | CytomX Therapeutics announced a public offering of $250.0 million in common stock and pre-funded warrants, with an addit | Mar 16, 2026 |
| FF | PRESS-RELEASE | bearish | 7/10 | FutureFuel Corp. reported a net loss of $49.4 million ($1.13 per diluted share) and negative Adjusted EBITDA of $38.3 mi | Mar 16, 2026 |
| CUE | PRESS-RELEASE | neutral | 3/10 | Cue Biopharma reported its fourth quarter and full year 2025 financial results. The press release announces financial re | Mar 16, 2026 |
| KYNB | PRESS-RELEASE | bearish | 6/10 | Kyntra Bio reported a significant year-over-year decline in revenue and wider net losses from continuing operations for | Mar 16, 2026 |
| BDTX | PRESS-RELEASE | mixed | 6/10 | Black Diamond Therapeutics reported financial results for Q4 and full year 2025, highlighted by a significant improvemen | Mar 16, 2026 |
| RFL | PRESS-RELEASE | mixed | 6/10 | Rafael Holdings reported Q2 FY2026 financial results with a net loss of $6.4 million, wider than the prior year's $4.6 m | Mar 16, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc Ltd. announced that NeuroThera Labs, in which it holds a 75% stake, has filed a patent application in Hong Kong | Mar 16, 2026 |
| AMRN | PRESS-RELEASE | neutral | 4/10 | Amarin Corporation announced that additional subgroup and mechanistic data from the REDUCE-IT trial will be presented at | Mar 16, 2026 |
| MIST | PRESS-RELEASE | mixed | 5/10 | Milestone Pharmaceuticals (MIST) announced new data from its Phase 3 trials showing minimal blood pressure effects and l | Mar 16, 2026 |
| LFCR | PRESS-RELEASE | mixed | 6/10 | Lifecore Biomedical reported strong financial results for the seven-month transition period ending December 31, 2025, wi | Mar 16, 2026 |
| APRE | PRESS-RELEASE | mixed | 6/10 | Aprea Therapeutics reported Q4 and full-year 2025 financial results, highlighted by early clinical proof-of-concept for | Mar 16, 2026 |
| LYB | PRESS-RELEASE | neutral | 3/10 | LyondellBasell announced the appointment of David Dennison as its new head of investor relations, effective May 8, 2026, | Mar 16, 2026 |